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PURPOSE. We seek to identify pathogenic mechanisms for diabetic retinopathy that can
become therapeutic targets beyond hyperglycemia and hypertension. We investigated if a
defective myogenic response of retinal arteries to increased perfusion pressure, which
exposes capillaries to increased pressure and flow, is associated with the onset of clinical
retinopathy.
METHODS. We examined prospectively the incidence of retinopathy in type 1 diabetic
individuals tested 4 years earlier for the retinal arterial myogenic response, and in a cross-
sectional study the prevalence of defective myogenic response in type 1 patients who had
diabetic retinopathy. Among these, we contrasted early-onset (after 15 6 2 years of diabetes,
E-DR; n ¼ 5) to late-onset (after 26 6 3 years of diabetes, L-DR; n ¼ 7) retinopathy. We
measured the myogenic response using a laser Doppler blood flowmeter after a change in
posture from sitting to reclining, which increases retinal perfusion pressure.
RESULTS. Five of seven participants who 4 years prior had a defective myogenic response had
now developed clinical retinopathy; as compared with only one of six participants who 4
years prior had a normal response (P ¼ 0.10). In the cross-sectional study, all participants had
normal retinal hemodynamics at steady state. In response to the postural change, only the E-
DR group showed defective myogenic response (P ¼ 0.005 versus controls, P ¼ 0.02 versus
L-DR) and abnormally high retinal blood flow (P ¼ 0.016 versus controls).
CONCLUSIONS. In type 1 diabetic patients, a defective myogenic response of retinal arteries to
pressure is not required for the development of clinical retinopathy, but is prominently
associated with an accelerated onset of retinopathy.
Keywords: type 1 diabetes, retinopathy, myogenic response, retinal blood flow, retinal
circulation, laser Doppler, accelerator, biomarker
After implementation of the lessons learned from theDiabetes Control and Complications Trial1 and the UK
Prospective Diabetes Study Group,2 the onset and progression
of diabetic retinopathy have been delayed substantially, but
predictable prevention remains beyond reach. The main reason
is that the glycemic levels that can cause retinopathy are lower
than the levels that patients can safely maintain with today’s
treatment modalities. Data from ethnically diverse populations
reveal that diabetic retinopathy begins to appear at HbA1c
levels of 6.5%, just above the upper limit of normal.3 So
consistent is this apparent threshold, that HbA1c of 6.5% or
higher has become a diagnostic criterion for diabetes.4
However, HbA1c less than 6.5% is an elusive target even for
patients committed to tight glycemic control, and may be
unsafe.5 An additional reason for the difficulty to prevent
retinopathy is the likely pathogenic contribution of factors that
we do not know and/or we do not routinely assess.
In practical terms, once we have intervened to control
blood glucose and blood pressure (BP) levels as well as it is
safely possible, we have nothing more to offer toward
predictable prevention or arrest of retinopathy. If, instead, we
knew about mechanisms that accelerate development or
progression in the context of even mild hyperglycemia and
normal systemic BP, and if such mechanisms were amenable to
measurements interpretable in the individual patient, we could
become more proactive. We would survey patients systemat-
ically for the pathogenic abnormality, attempt to develop
adjunct interventions against such an abnormality, and use the
interventions in a timely and selective manner in the patients
expected to benefit from them.
Retinal hemodynamic measurements are an attractive
approach to identify abnormalities that precede clinical
retinopathy because they relate directly to the vessels, and
can be performed noninvasively in humans. We reported that
contemporary type 1 diabetic individuals, relatively well-
controlled and with no or minimal retinopathy, do not show
abnormalities of the retinal circulation at steady state.6
However, when we imposed a challenge, a simple change in
position from sitting to reclining, a fraction of such patients
without clinical retinopathy showed a functional abnormality,
manifested as lack of arterial constriction in response to the
increased perfusion pressure induced by the postural change.7
The constriction of arteries to pressure is termed ‘‘myogenic
response’’ because it is intrinsic to the arterial smooth muscle
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cells; in the retina as in other organs it dampens the
transmission of pressure to capillaries and parenchyma,
thereby protecting against microvascular and organ damage.8
Thus, the absence of constriction or paradoxical dilation of
retinal arteries that we had observed in approximately half of
our patients still free of clinical retinopathy reflects a defective
myogenic response, and could be a mechanism for accelerating
the development of retinopathy. To gain insight into the
relationship between a defective myogenic response of retinal
vessels and the development of retinopathy, we asked two
questions: whether a defective myogenic response (1) predict-
ed the appearance of retinopathy (prospective arm of the
study), and (2) was present in all cases of clinical retinopathy
of recent onset (cross-sectional arm of the study).
METHODS
Design and Participants
The procedures followed the Declaration of Helsinki, and the
institutional review boards of the Massachusetts Eye and Ear
Infirmary (MEEI) and of the Massachusetts General Hospital
(MGH) approved the study. The participants gave written
informed consent.
The study had two arms. One was a prospective-longitudi-
nal cohort study, based on the type 1 diabetic individuals in
whom we had measured the myogenic response of retinal
vessels to pressure 4 years earlier, when they had no
retinopathy.7 There were no criteria of exclusion. We
attempted to contact all 17 patients, but only 13 could be
reached or responded. The second arm consisted of a cross-
sectional study of type 1 diabetic individuals age 18 to 50 years
who had developed retinopathy within approximately 2 years,
and age- and sex-matched nondiabetic individuals. The 2 years
maximal known duration of retinopathy was intended to
permit us to study early retinopathy, before long-standing or
severe structural abnormalities of vessels might impose their
own changes on retinal hemodynamics. To capture a potential
accelerator role of the defective myogenic response, we
recruited individuals who had developed diabetic retinopathy
early in the course of the disease. We chose as threshold 18 or
fewer years of diabetes, because at such duration fewer than
20% of contemporary type 1 diabetic patients have any
retinopathy.9 We also recruited individuals with late onset of
retinopathy, to compare and contrast with the early-onset
group. The nondiabetic participants, matched for age and sex,
had no history of diabetes and had HbA1c levels lower than 6%.
The exclusion criteria were the same as in our previous studies
of retinal hemodynamics6,7: smoking; pregnancy; systemic
diseases other than type 1 diabetes, in particular hypertension
and renal disease; retinal diseases other than diabetic
retinopathy; and use of angiotensin-converting enzyme inhib-
itors, angiotensin receptor blockers, nonsteroidal anti-inflam-
matory drugs including low-dose aspirin, and high doses of
vitamin E. Nine of the 12 diabetic participants were taking
allowed drugs: contraceptives, antidepressants, lipid-lowering
medications, inhalers for asthma, and thyroid replacement
medications.
Procedures and Hemodynamic Measurements
In both the prospective and the cross-sectional studies, after
giving informed consent, the participants underwent an eye
examination inclusive of measurement of the IOP using
Goldmann applanation tonometry, pupil dilation with 1%
tropicamide, and seven-field stereo fundus photography. A
blood sample was obtained to measure HbA1c. The cross-
sectional study included also the hemodynamic measurements,
performed in all participants at the same time of day, between
3:00 PM and 5:00 PM. In the diabetic participants, the
hemodynamic studies were performed only if the capillary
blood glucose was between 70 and 220 mg/dL to prevent
confounding influences of hypoglycemia or severe hypergly-
cemia.
The retinal hemodynamic measurements were acquired
noninvasively through a dilated pupil using a laser Doppler
blood flowmeter (CLBF 100; Canon, Tokyo, Japan). The
instrument measures arterial blood column diameter and
centerline blood speed in individual retinal vessels; the blood
flow rate in microliters per minute is calculated automatically
as the product of the cross-sectional area of the artery at the
measurement site and the average blood speed, assuming a
circular arterial cross-section. Measurements are reproducible,
and can be repeated at the same vessel site.10 As in all our
previous studies,6,7 the measurements were performed at the
superior temporal artery because the lesions of diabetic
retinopathy are more prevalent in the superior temporal than
in the other quadrants of the retina.11
Baseline measurements were acquired after a 20-minute
equilibration period in the sitting position. The measurements
included systolic, diastolic, and mean brachial artery BP and
heart rate (Keller Vital Signs Monitor; Keller Medical Special-
ties, Antioch, IL, USA); ocular perfusion pressure (OPP),
calculated using the formula OPP¼ 2/3 mean arterial pressure
– IOP; and superior temporal artery diameter, blood speed, and
blood flow in the left eye. The retinal circulatory parameters
were then measured after a postural change from sitting to
reclining, as in our previous work.7 Briefly, the participants
were asked to recline on their right side, with their head
supported by a foam wedge making an angle of 248 from the
horizontal, for 30 minutes while brachial BP and heart rate
were automatically measured from the left arm and recorded
every 5 minutes. At the end of the 30 minutes of reclining, the
hemodynamic measurements were repeated in the left eye at
the same arterial site used at baseline. While reclining, there is
an elevation of the OPP; the change in OPP was calculated
following the formula validated by direct measurements of the
OPP using ophthalmodynamometry.12,13 The final set of
measurements was taken after the participants had returned
to the sitting position for 20 minutes.
Recruitment of study participants was through the MGH
Diabetes Center. All procedures were performed at the MEEI;
the HbA1c was measured by the Clinical Laboratory, and the
retinal photographs were taken in the Retina Photography
Service. Retinopathy was diagnosed and graded on the
photographs on the basis of the Early Treatment Diabetic
Retinopathy Study (ETDRS) severity scale: level 10, absent
retinopathy; level 20, microaneurysms only; level 35, micro-
aneurysms and hard exudates. The grader (LS) was masked to
all hemodynamic results. In statistical comparisons we
analyzed the ETDRS levels both for the worst eye (as per
convention in grading diabetic retinopathy) and for the left
eye, on which the hemodynamic studies were performed.
Statistical Analysis
Data were analyzed for normality using the Shapiro-Wilk and
the Shapiro-Francia tests; normally distributed data were
summarized with the mean 6 SD, nonnormally distributed
data with the median and interquartile range. All statistical
analyses were performed using the Stata 12 software (Stata
Statistical Software: Release 12; StataCorp LP, College Station,
TX, USA) and 2-tailed tests. Continuous data normally
distributed were analyzed using ANOVA followed by the
Bonferroni adjustment for multiple comparisons; except for
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duration of diabetes, which was compared between two
groups using the unpaired t-test. Continuous data nonnormally
distributed were analyzed using nonparametric tests: the
Mann-Whitney rank-sum test when comparing two groups; or
the Dunn’s test, in which the Kruskal-Wallis test is followed by
a Bonferroni adjustment for multiple comparisons. Categorical
data were analyzed using Fisher’s exact test.
RESULTS
Prospective Study
Among the 17 type 1 diabetic individuals who had their retinal
circulation tested in response to the postural change 4 years
earlier while still free of clinical retinopathy,7 approximately
half had manifested a defective myogenic response; that is, a
failure to constrict (or even paradoxical dilation of) the retinal
arteries in response to the postural change. We sought to
uncover whether the abnormality would predict the develop-
ment of retinopathy. Table 1 shows the results in the 13
participants who responded to our recall. Of the participants
who 4 years prior had manifested a defective myogenic
response, five of seven had developed clinical retinopathy. In
contrast, of the participants who 4 years prior had shown a
normal vasoconstrictor response only one of six had developed
retinopathy (P ¼ 0.10). The current age and HbA1c were
similar in the two groups; the current diabetes duration tended
to be longer, albeit not significantly (P¼ 0.06), in the patients
who had manifested 4 years earlier a defective myogenic
response. When we compared the patients who did and those
who did not develop retinopathy, we observed that the pattern
of diameter change measured 4 years earlier was significantly
different in the two groups. Those who did develop
retinopathy had shown no change or an increase in retinal
diameter in response to reclining (3.3% [0.0%–7.4%]), whereas
the patients who did not develop retinopathy had shown
mostly diameter constriction (4.0% [6.1%–0.0%]) (P ¼
0.010).
Cross-Sectional Study
We investigated the prevalence of a defective myogenic
response in individuals who had already developed clinical
retinopathy. Based on the duration of diabetes at onset of
retinopathy, we defined two groups: early-onset diabetic
retinopathy (E-DR) and late-onset diabetic retinopathy (L-DR).
Table 2 shows the characteristics of the groups compared. The
E-DR participants were younger, had developed diabetes at the
same age as the L-DR participants, and at the time of study had
a duration of diabetes of 15 6 2 years. Taking into account that
they had retinopathy of up to a 2-year duration, the onset of
retinopathy had been as early as after 11 to 15 years of
diabetes. The L-DR participants had a duration of diabetes of 26
6 3 years (P ¼ 0.0001 versus E-DR group), and had thus
developed retinopathy after 21 to 27 years of diabetes. The E-
DR participants had higher HbA1c levels. One E-DR participant
in particular had a very high HbA1c value (11%). We thus
tested how the data would be affected by the exclusion of this
individual. The HbA1c of the E-DR group would become 7.6%
6 0.5%, not statistically different from the 7.1% 6 0.6% of the
L-DR group; while all hemodynamic findings would remain the
same and maintain the statistically significant differences
recorded when including the individual with 11% HbA1c.
The individual was thus included in all computations.
Both the E-DR and the L-DR participants had normal retinal
hemodynamic measurements at steady state (Table 3). In
contrast, in response to the challenge imposed by the postural
change from sitting to reclining, the E-DR group showed
abnormalities not shown by the L-DR group (see Fig.). The E-
DR group failed to constrict the diameter of the retinal artery in
TABLE 1. Prospective Study: Development of Clinical Retinopathy in the Cohort of Type 1 Diabetic Participants Tested for the Myogenic Response 4
Years Earlier When Still Free of Retinopathy
Participants
Change in
Arterial Diameter
on Reclining,* %
Current
Age, y
Sex,
F/M
Current Diabetes
Duration, y
HbA1c,
% Retinopathy
ETDRS Level†
OD OS
1 þ7.4 23 F 19 8.5 Yes 20 20
2 0 27 M 19 6.3 No 10 10
3 þ5.9 45 F 20 8.4 Yes 10 20
4 0 41 F 25 7.0 Yes 20 20
5 þ0.7 29 F 12 6.6 Yes 35 20
6 0 40 M 18 7.0 No 10 10
7 þ7.8 32 M 27 6.9 Yes 20 20
0.7 (0.0:7.4)‡ 34 6 8 4/3 20 6 5§ 7.2 6 0.8 5/7jj
8 3.8 24 F 20 7.5 No 10 10
9 4.2 44 M 11 6.3 No 10 10
10 4.0 40 F 18 6.3 No 10 10
11 3.3 31 F 17 7.6 Yes 20 20
12 15.0 49 M 11 Not obtained No 10 10
13 6.1 46 F 11 7.2 No 10 10
4.1 (6.1:3.8) 39 6 10 4/2 15 6 4 7.0 6 0.6 1/6
Data are Mean 6 SD or median and interquartile range (except for categorical variables).
* As measured 3.9 6 0.2 years earlier, when all diabetic subjects were free of retinopathy, and as reported in Ref. 7. The change in retinal arterial
diameter, representing the myogenic response, was measured upon the postural change from sitting to reclining described in Methods. Patients 1 to
7 failed to show the decrease in arterial diameter that represents the normal myogenic response to pressure. Patients 8 to 13 showed a normal
myogenic response. All participants were Caucasian.
† ETDRS retinopathy level graded on fundus photographs: 10, no retinopathy; 20, microaneurysms only; 35, microaneurysms and hard exudates.
‡ P ¼ 0.0026 versus the normal arterial constriction shown by subjects 8 to 13.
§ P¼ 0.06 versus subjects with normal arterial constriction.
jj P¼ 0.10 by Fisher’s exact test versus incidence among the subjects with normal arterial constriction.
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response to pressure: among the five participants, four showed
paradoxical dilation and one normal constriction; and this
pattern was different from both the pattern of the control
group (P ¼ 0.005) and the L-DR group (P ¼ 0.020). The L-DR
group was not significantly different from the control group,
with six of the seven L-DR participants constricting normally
and one showing dilation. The E-DR participants manifested a
defective myogenic response despite the fact that the changes
in systemic BP and OPP while reclining were similar to those in
the other groups. The reclining systolic and diastolic BP were,
respectively (in mm Hg), 99 6 11 and 55 6 8 in controls, 95 6
2 and 58 6 6 in the E-DR participants, and 94 6 10 and 57 6 7
in the L-DR participants. The OPP while reclining, estimated
from mean arterial pressure (MAP)reclining – IOP,
7,12 was (in mm
Hg) 55 6 9 in controls, 51 6 5 in the E-DR participants, and 49
6 5 in the L-DR participants. Consequently, the increase in
OPP induced by reclining, which represents the driving
stimulus for the myogenic arterial constriction, was similar in
all groups: 15% (11%–20%) in the controls, 15% (9%–26%) in
the E-DR group, and 21% (10%–30%) in the L-DR group (P ¼
NS). The blood speed response to reclining was especially
variable among the L-DR participants, but did not differ among
the groups. In agreement with the fact that blood flow is the
product of the arterial diameter and blood speed, the lack of
diameter constriction in the E-DR group resulted in an
abnormally increased retinal blood flow (P ¼ 0.016 versus
controls). In contrast, in the L-DR group, the blood flow
changes were not different from controls (P ¼ 0.60).
DISCUSSION
This report provides four new insights toward reconstructing
the pathogenesis of retinal microangiopathy in contemporary
type 1 diabetic patients. First, at steady state, the retinal
circulation of these relatively well-controlled individuals does
not show abnormalities of vessel diameter or blood speed and
flow, even in the presence of established retinopathy up to
ETDRS level 35. This is a substantial departure from the many
abnormalities reported at steady state in the retinal circulation
of diabetic patients with and without retinopathy in the early
1990s.14,15 Second, the need for an adaptation of the retinal
circulation, as physiological as that required by an increased
perfusion pressure due to a postural change, uncovers in some
patients a defective myogenic response of retinal arteries that
tends to predict the onset of clinical retinopathy. Third, many
patients who developed retinopathy after prolonged diabetes
duration show a normal myogenic response. Fourth, and
operationally most important, when the onset of retinopathy
occurs after short diabetes duration, the myogenic response is
prominently defective.
The observations in the participants with late-onset
retinopathy make clear that a defective myogenic response to
pressure is not a requirement for the development of clinical
retinopathy. In those patients, in excellent glycemic control
and normotensive, retinopathy is likely the consequence of
total glycemic exposure. This best-documented risk factor for
retinopathy in type 1 diabetes16 predicts that, when of long
duration, even minimal hyperglycemia becomes an effector of
vascular damage. If a defective myogenic response is not
required for the development of retinopathy, then it cannot be
an unqualified biomarker of retinopathy risk, insofar as the
absence of the marker would not exclude the development of
retinopathy at some point in time.
The defective myogenic response to pressure may instead
realistically claim a role as ‘‘accelerator’’ of retinopathy
development. The prospective study showed that it was
mostly the individuals with a defective myogenic response
who went on to develop clinical retinopathy within 4 years,
TABLE 2. Cross-Sectional Study: Characteristics of the Type 1 Diabetic and Nondiabetic Participants
Control, n ¼ 15 E-DR, n ¼ 5 L-DR, n ¼ 7 P
Age, y 32 6 8 27 6 6 38 6 7 E-DR vs. L-DR ¼ 0.05
Sex, F/M 9/6 2/3 6/1 NS
Race, Caucasian/Asian 14/1 4/1 6/1 NS
Age at onset of diabetes, y NA 12 6 5 12 6 6 NS
Duration of diabetes, y NA 15 6 2 26 6 3 E-DR vs. L-DR <0.0001
HbA1c, % 5.4 6 0.2 8.4 6 1.8 7.1 6 0.6 E-DR and L-DR vs. C <0.0001
E-DR vs. L-DR ¼ 0.03
Glucose, mg/dL 104 6 12 161 6 42 182 6 41 E-DR and L-DR vs. C < 0.02
SBP, mm Hg 109 6 20 119 6 12 111 6 7 NS
DBP, mm Hg 74 6 12 76 6 9 75 6 7 NS
IOP OS, mm Hg 13 6 2 16 6 3 15 6 4 NS
OPP OS, mm Hg* 47 6 8 45 6 8 41 6 2 NS
EDTRS retinopathy level, OS NA 35 (3535) 15 (10†35) NS
ETDRS retinopathy level, worst eye NA 35 (3535) 20 (10†35) NS
The data are mean 6 SD, except for sex, race, and ETDRS levels. ETDRS levels are medians (25th–75th percentiles). All measurements were
performed immediately before the hemodynamic studies. C, control subjects; DBP, diastolic BP; NA, not applicable; NS, not significant; SBP systolic BP.
* Calculated using the standard formula OPP¼ 2/3 MAP – IOP.
† One L-DR participant was enrolled in the study on the basis of previous signs of early retinopathy, which were not detectable in the retinal
photographs performed for this study.
TABLE 3. Cross-Sectional Study: Baseline Retinal Hemodynamic Parameters in the Type 1 Diabetic and Nondiabetic Participants
Control, n ¼ 15 E-DR, n ¼ 5 L-DR, n ¼ 7 P
Diameter, lm 113 (108116) 109 (102112) 118 (111122) NS
Blood speed, mm/s 36 (3040) 31 (3133) 33 (3140) NS
Flow, lL/min 10 (815) 10 (811) 11 (913) NS
The data are median and interquartile range (25th 75th percentiles).
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FIGURE. Cross-Sectional study: retinal hemodynamic parameters in response to the change in posture from sitting to reclining in the type 1 diabetic
participants with clinical retinopathy and nondiabetic participants. The box plots present the data for the 15 controls, 5 type 1 diabetic participants
with E-DR, and 7 type 1 diabetic participants with L-DR. Each box plot shows the 10th, 25th, 50th (median), 75th, and 90th percentile of the
indicated parameters. Values above the 90th percentile are plotted as points. *P ¼ 0.005 and **P¼ 0.020 for indicated comparisons.
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despite having HbA1c levels similar to, and diabetes duration
not statistically different from, the participants who had a
normal myogenic response. In complementary fashion, the
cross-sectional study showed that the participants who had
already developed clinical retinopathy after a remarkably short
diabetes duration9 were those with a defective myogenic
response and an abnormally increased retinal blood flow
response to pressure. We cannot exclude that a defective
myogenic response to pressure could be an epiphenomenon in
a process that leads to accelerated retinopathy via mechanisms
that we do not yet know. However, concepts that are known
indicate that a defective myogenic response could have a
pathogenic role for diabetic retinopathy. According to Poui-
selle’s law, blood flow is related to the fourth power of the
vessel radius. Retinal arteries that do not constrict normally to
increased perfusion pressure allow a larger fraction of such
pressure to reach the capillaries, where it can facilitate the
dilations that cause microaneurysms, the leakage that causes
edema, and the ruptures that cause hemorrhages.17 Of note,
these hemodynamic mechanisms, when working in the
opposite direction, can be protective against diabetic retinop-
athy. For example, the protection exerted by high myopia17,18
has been attributed to the attenuation of the perfusion
pressure along the longer arterioles of the elongated myopic
eye, with resultant protection of the capillary bed.17,19
The original hemodynamic hypothesis of diabetic retinop-
athy was formulated before the era of tight glycemic control,
and was based on the evidence of increased retinal blood flow
at steady state in diabetes. The hypothesis was thus centered
on hyperglycemia as the direct inducer of increased flow, with
the effects eventually compounded by loss of autoregulation
and systemic hypertension.14 Given that contemporary, well-
controlled type 1 patients show normal retinal blood flow at
steady state, the hemodynamic hypothesis requires an update.
The update could be centered on the defective myogenic
response, because this abnormality (1) is detected in the
absence of clinical retinopathy and may predict its onset, (2) is
associated with increased retinal blood flow, and (3) is present
when retinopathy has an accelerated onset. In this new
formulation, the hemodynamic hypothesis incorporates a
functionally better defined mechanism (defective myogenic
response), with a more specific role (accelerator), and a more
selective epidemiology (early-onset retinopathy rather than
retinopathy in general). The added facts that the pattern of the
myogenic response is repeatable when the individual patient is
retested months apart,7 and readily interpretable being a
qualitative outcome, make the defective myogenic response of
retinal vessels a reasonable target of potential adjunct drugs.
The main limitation of this study is the small number of
patients tested. Additionally, the study addressed solely
patients with type 1 diabetes who did not take vasoactive
drugs; thus, it is unknown whether the findings can be
extended to the much more common setting of patients with
type 2 diabetes, often taking drugs for systemic hypertension.
This is, however, not unlikely, because a defective myogenic
response of retinal vessels to a pressure stimulus (increased
systemic BP induced by isometric exercise) has been noted
also in type 2 diabetic patients, some treated with vasoactive
drugs, who had retinopathy with or without macular edema.20
Observations in type 2 diabetic patients have revealed that a
loss of myogenic constriction to pressure occurs also in
arteries other than the retinal arteries, and is selective for the
pressure stimulus insofar as the response to noradrenergic
agonists is intact.21 When addressing mechanisms, it must be
noted that, in addition to pressure, the retinal vessels of
diabetic patients show abnormal responses also to light
flickering22 and oxygen inhalation.23 Whether these abnormal-
ities coexist in the same individual and stem from the same
mechanism, is currently unknown. Given that the myogenic
response to pressure is a well-defined mechanism of vascular
homeostasis that is already actively investigated as a pharma-
cologic target,8 its early defect could profitably become the
focus of investigations to disable an accelerator of diabetic
retinopathy.
Our new observations that a defective myogenic response
to pressure of retinal vessels can be an accelerator of
retinopathy, together with the observations that a defective
myogenic response to pressure is prevalent in type 2 diabetes,
and is present in sight-threatening retinopathy, call for a
definitive longitudinal cohort study. If a fully powered study
confirmed that a defective myogenic response predicts an
accelerated onset and/or course of diabetic retinopathy, there
will be rationale and impetus to developing targeted drugs. In
the meantime, our findings renew the emphasis on monitoring
and treating aggressively in our patients any increase in
systemic BP, because a defective vascular constriction magni-
fies widely the effects of any increment in BP on retinal
vessels.14
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